Qiagen stock weighs stronger Q3 margins against suspended outlook

QIAGEN's third-quarter performance gave investors a stronger operating picture, but the pending EQT transaction continues to limit the company's financial outlook. In its results released on Wednesday, November 4, QIAGEN reported higher sales and adjusted margins while suspending full-year 2026 guidance until the transaction is resolved.

The QIAGEN investor relations release said third-quarter sales rose 3% year over year to 548 million US dollars, both on a reported basis and at constant exchange rates. The result exceeded the company's outlook for constant-currency growth of about 1% to 2%.

Margins improve as guidance stays suspended

Adjusted operating income increased 6% to 167 million US dollars, lifting the adjusted operating margin to 30.4% from 29.6% a year earlier. QIAGEN attributed the improvement to sales growth, a larger contribution from higher-margin consumables and efficiency gains, while continuing to invest in Parse Biosciences after its late-2025 acquisition.

Consumables and related revenues grew 3% at constant exchange rates and represented 91% of sales. Instrument revenue increased 1% at constant exchange rates. Sales from QIAGEN's growth pillars rose 7% to 415 million US dollars, while the rest of the portfolio declined 7% at constant exchange rates.

Reported diluted earnings per share fell to 0.51 US dollars from 0.60 US dollars. Adjusted diluted earnings per share increased to 0.65 US dollars from 0.61 US dollars and exceeded the company's outlook for at least 0.62 US dollars at constant exchange rates. Operating cash flow reached 447 million US dollars for the first nine months.

Deal timetable remains central

QIAGEN has suspended its 2026 outlook and said it will not provide financial guidance while the EQT Private Equity transaction is pending. The company therefore enters the next reporting phase with operating momentum visible in the latest quarter, but with less earnings visibility for investors until the takeover process advances.

QIAGEN stock traded at 45.34 euros on Lang & Schwarz at 11:12 CET on Thursday, November 12, 0.07% below the Xetra close of Wednesday, November 11. The modest gap leaves the market focused on execution, the transaction timetable and the eventual return of formal guidance rather than on a new earnings forecast.

European equities remain sensitive to interest-rate expectations and company-specific takeover activity; investors can follow the AEX market environment.

Further updates will depend on the next steps in the EQT process and on when QIAGEN can restore its full-year outlook. Follow More news and analyses on Qiagen stock.